Cagrilintide: A Tracking Guide for a Long-Acting Amylin Analog

Cagrilintide is a long-acting amylin analog being developed as a weight-management drug. Amylin is co-secreted with insulin and signals satiety, slows gastric emptying, and reduces postprandial glucagon. The most visible clinical program combines cagrilintide with semaglutide, called CagriSema, with Phase 3 REDEFINE data showing roughly 22 percent average weight loss and a regulatory filing expected in late 2026. In practice cagrilintide is now discussed far more often as one half of CagriSema than as a standalone; if that combination is what you are tracking, see the dedicated CagriSema guide. Cagrilintide alone is not yet approved as a standalone product in major markets.

What it is supposed to do

By activating amylin and calcitonin receptors, cagrilintide is intended to reduce hunger and food intake. The CagriSema trials are designed around the idea that combining an amylin analog with a GLP-1 receptor agonist produces greater weight loss than either alone, by hitting complementary appetite pathways.

Typical protocol shape

• Route: subcutaneous injection
• Frequency: once weekly, similar to semaglutide
• Dose: trial dose ranges have included 0.3 mg up to 2.4 mg weekly, with gradual titration
• Titration: stepwise increases roughly every four weeks, mirroring GLP-1 titration logic
• Duration: weight effects build over months

If you are using it as part of a CagriSema-style stack, the semaglutide titration interacts with cagrilintide tolerability — gut effects can stack.

What to track daily

• Morning fasted weight
• Hunger ratings before each meal
• Nausea, fullness, or reflux ratings
• Meals skipped or undereaten
• Hydration

What to track weekly

• Weight, averaged across the week
• Waist at the navel
• Body composition by a consistent method
• Training performance and any loss of strength or endurance
• Mood, especially if appetite suppression is heavy

Bloodwork worth doing

• Baseline and ongoing fasting glucose, insulin, HbA1c
• Lipid panel
• Liver and kidney panels
• Thyroid function, especially if you have a family history of thyroid concerns; this is standard caution with this drug class

Realistic expectations

Trial data for CagriSema show weight loss in a range broadly comparable to or somewhat above semaglutide monotherapy, with the usual gastrointestinal side-effect pattern. Cagrilintide alone is less dramatic. For self-experimenters, the honest framing is: this is an appetite drug, and most of the effect runs through eating less. Tracking what you actually eat is more informative than tracking the scale.

Common mistakes

• Titrating faster than the trial schedule and getting hit with avoidable nausea
• Not tracking protein intake, then losing lean mass alongside fat
• Combining with other appetite suppressants without a plan
• Treating weekly dosing as forgiving — missing a dose still matters, and restarting at a high dose after a gap can be rough

A tracking template

• Week 0: baseline bloodwork, body composition, two-week food log
• Weeks 1–4: starting dose, daily symptom and intake log in Peptid AI
• Week 4: first titration step if tolerated
• Weeks 5–16: continued titration as planned; repeat bloodwork at week 12
• Weeks 17–24: maintenance phase; evaluate whether weight loss has plateaued
• Washout: track weight, appetite, and intake for at least 8 weeks after stopping

Bottom line

Cagrilintide has real Phase 3 data behind it, mostly in combination with semaglutide. The mechanism is coherent and the side-effect profile is recognizable from related drugs. If you are using it, treat it like the metabolic drug it is: bloodwork, food logging, protein targets, and a realistic plan for what happens after the cycle ends.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.